Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Can-Fite Biopharma Ltd ADR
(NY:
CANF
)
2.090
-0.052 (-2.42%)
Official Closing Price
Updated: 8:00 PM EDT, May 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
9,250
Open
2.120
Bid (Size)
2.050 (2)
Ask (Size)
2.140 (4)
Prev. Close
2.142
Today's Range
2.053 - 2.120
52wk Range
1.810 - 3.330
Shares Outstanding
515,746,293
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
May 10, 2024
Via
ACCESSWIRE
Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study
May 09, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Performance
YTD
+0.97%
+0.97%
1 Month
-11.06%
-11.06%
3 Month
+1.46%
+1.46%
6 Month
+7.73%
+7.73%
1 Year
-33.01%
-33.01%
More News
Read More
Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602
May 06, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can Fite Biofarma: Q4 Earnings Insights
March 28, 2024
Via
Benzinga
Recap: Can Fite Biofarma Q3 Earnings
November 30, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
April 25, 2024
Via
Benzinga
Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal
April 25, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
April 15, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
April 03, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
CANF Stock Earnings: Can Fite Biofarma Beats EPS, Beats Revenue for Q4 2023
March 28, 2024
Via
InvestorPlace
Can-Fite Reports 2023 Financial Results and Clinical Update
March 28, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
March 11, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada
February 28, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
January 30, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study
January 29, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies
December 20, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan
December 18, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development
December 04, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update
November 30, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Why Is Liver Cancer Focused Can-Fite BioPharma Stock Trading Higher Today?
November 21, 2023
Via
Benzinga
Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson
November 21, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track
November 01, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action
October 30, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs
October 26, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Matson To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Tuesday
October 24, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.